RxDoctor Payments Data

William Batty, MD

Internal Medicine · Fullerton, CANPI 1447246434

Payments from drug & device makers

$414in general payments, 2019–2025

Across 20 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$121
  • Novo Nordisk$68
  • Pfizer$67
  • Abbott$62
  • AbbVie$57
  • Bayer$25
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen7$121
Novo Nordisk3$68
Pfizer2$67
Abbott3$62
AbbVie3$57
Bayer1$25
Novartis1$14

How this compares

$414 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$155,120
Medicare patients
404
Services billed
1,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$130,417
JanuviaSitagliptin Phosphate45$56,811
XareltoRivaroxaban18$27,115
JardianceEmpagliflozin13$20,739
Atorvastatin Calcium1,205$12,637
MounjaroTirzepatide11$10,524
Levothyroxine Sodium730$9,904
OzempicSemaglutide12$9,798
Losartan Potassium499$6,114
SynthroidLevothyroxine Sodium81$5,687
Amlodipine Besylate747$4,452
Rosuvastatin Calcium268$4,343
Febuxostat16$4,213
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,720
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$130,417133 claims
Novo NordiskOzempic$68$9,79812 claims
AbbVieSynthroid$57$5,68781 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →